| abstract |
A pharmaceutical composition comprising a 1: 3 ratio of nivolumab to ipilimumab, comprising 4.62 mg / ml ipilimumab, 1.54 mg / ml nivolumab, 18.46 mM tris hydrochloride (HCl), sodium citrate 1.54 mM dihydrate, 96.15 mM NaCl, 1.15% w / v mannitol, 93.85 µM pentetic acid and 0.012% w / v PS80. |